Member Info for B_Positive

This needs news if it wants to hold the rise

+£3.3m cash secured

+Full scale production to restart and generating revenues

+Massive massive market for African hardwood

+Warrants at a 200% premium to current share price

+Small debt repayment deferred to DECEMBER 2026 with 0 interest

Warrants at 0.125p as well.

200% from here.

Going to gap up Monday even without an RNS over into the 0.030s.

With an RNS and then well into the 0.060s at least.

Placing churned. Can't buy a bean.

News to come.

94mil buy just in paying premium.

Leaky leaky.

Strong finish coming.

Just in March.

Big things happening here.

Debts cleared.

More skin in the game from the head honcho's.

Update on U.S Aerospace Project

Ethernity Networks (AIM: ENET.L; OTCMKTS: ENETF), a leading supplier of data processing semiconductor technology for networking appliances, provides an update on the $1.05m contract signed with a Tier 1 U.S.-based aerospace system products provider (the "Customer").

As previously disclosed, the $1.05 million licensing deal with the Tier-1 U.S. aerospace vendor involves Ethernity delivering its silicon-tuned software to enable specific networking functionalities on the Customer's unique platform.

The Company obtained U.S Government approval for the project in September 2024, and over the course of six months, the Company has successfully completed all scheduled deliveries focused on porting Ethernity's existing silicon tuned software onto the customer's platform, and has invoiced $890,000 to date. Additionally, the Company is pleased to have received the highest performance ratings across all aspects of the contract so far, including technical support, adherence to scheduled deliveries, and overall management.

It is anticipated that the contract will be extended by an additional $290,000 to allocate dedicated development resources for additional functionalities beyond the original scope, with implementation planned over the next three months. Combined with the remaining $160,000 from the original contract, the additional $290,000 will bring the total anticipated collection to $450,000 in the near term. The Company anticipates further revenue from the Customer during H2 2025.

Strap in for potentially 100 bags with the right news.

Can't buy a bean.

Strong finish coming.

Just in March.

Big things happening here.

Debts cleared.

More skin in the game from the head honcho's.

Update on U.S Aerospace Project

Ethernity Networks (AIM: ENET.L; OTCMKTS: ENETF), a leading supplier of data processing semiconductor technology for networking appliances, provides an update on the $1.05m contract signed with a Tier 1 U.S.-based aerospace system products provider (the "Customer").

As previously disclosed, the $1.05 million licensing deal with the Tier-1 U.S. aerospace vendor involves Ethernity delivering its silicon-tuned software to enable specific networking functionalities on the Customer's unique platform.

The Company obtained U.S Government approval for the project in September 2024, and over the course of six months, the Company has successfully completed all scheduled deliveries focused on porting Ethernity's existing silicon tuned software onto the customer's platform, and has invoiced $890,000 to date. Additionally, the Company is pleased to have received the highest performance ratings across all aspects of the contract so far, including technical support, adherence to scheduled deliveries, and overall management.

It is anticipated that the contract will be extended by an additional $290,000 to allocate dedicated development resources for additional functionalities beyond the original scope, with implementation planned over the next three months. Combined with the remaining $160,000 from the original contract, the additional $290,000 will bring the total anticipated collection to $450,000 in the near term. The Company anticipates further revenue from the Customer during H2 2025.

Strap in for potentially 100 bags with the right news.

Just in March.

Big things happening here.

Debts cleared.

More skin in the game from the head honcho's.

Update on U.S Aerospace Project

Ethernity Networks (AIM: ENET.L; OTCMKTS: ENETF), a leading supplier of data processing semiconductor technology for networking appliances, provides an update on the $1.05m contract signed with a Tier 1 U.S.-based aerospace system products provider (the "Customer").

As previously disclosed, the $1.05 million licensing deal with the Tier-1 U.S. aerospace vendor involves Ethernity delivering its silicon-tuned software to enable specific networking functionalities on the Customer's unique platform.

The Company obtained U.S Government approval for the project in September 2024, and over the course of six months, the Company has successfully completed all scheduled deliveries focused on porting Ethernity's existing silicon tuned software onto the customer's platform, and has invoiced $890,000 to date. Additionally, the Company is pleased to have received the highest performance ratings across all aspects of the contract so far, including technical support, adherence to scheduled deliveries, and overall management.

It is anticipated that the contract will be extended by an additional $290,000 to allocate dedicated development resources for additional functionalities beyond the original scope, with implementation planned over the next three months. Combined with the remaining $160,000 from the original contract, the additional $290,000 will bring the total anticipated collection to $450,000 in the near term. The Company anticipates further revenue from the Customer during H2 2025.

Strap in for potentially 100 bags with the right news.

Next week is going to be explosive

News is overdue and can start rolling in shortly

Last orders coming in

So much coming

+CE MARK

+FDA APPROVAL

+UK Expansion

+Europe Expansion

+US Expansion

+UAE Expansion as per LinkedIn

+National rollout in UK for Stroke testing

+National rollout in the UK for cardiovascular testing

+New contracts

+Grants

+Other wildcards

Over £3.0M in the coffers + additional revenues and grant cash = fully funded for 2025.

Now revenues growing on top.

Great stuff overall.

Last year 3 bags after the raise. I fancy 15-20 bags this time considering the magnitude of expansion coming here from both domestic and overseas.

Endorsement is huge.

Dr Gino Miele, CEO of genedrive plc, said: "We are delighted that our CYP2C19 rapid genetic test is being assessed for use in ACS and PCI procedures in addition to current clinical recommendations by NICE for use prior to prescription of Clopidogrel in IS and TIA. With clinical recommendations for CYP2C19 genetic testing for IS, TIA and ACS, and with rapid genetic testing within 24 hours being recommended if clopidogrel is being considered, our CYP2C19 test is well positioned to enable this intervention and care pathway change, significantly improving patient outcomes whilst at the same time freeing healthcare resources and finances."

Dr Jaydeep Sarma, Consultant Interventional Cardiologist in Greater Manchester, said: "The Greater Manchester Regional Primary PCI service operates 24 hours a day, 7 days a week, 365 days a year. Thousands of patients are seen rapidly for life saving interventions from across the region each year and it's essential that their treatments are optimised as quicky as possible. Integration of this rapid test into routine practice means we can get patients on the right treatment the first time, improving outcomes for our patients and the service as a whole."

Professor Maciej Tomaszewski, Deputy Director at the British Heart Foundation Manchester Centre of Research Excellence, said: "This is fantastic example of pharmacogenomics research in action, which has the potential to change clinical practice in cardiology clinics, wards and hospitals. The BHF Manchester CRE supports cardiovascular pharmacogenomics research and the follow up implementation programmes across the spectrum of cardiovascular diseases."

Bill Newman, Professor of Translational Genomic Medicine at University of Manchester, Consultant in Genomic Medicine at MFT, and a researcher with the National Institute for Health and Care Research (NIHR) Manchester BRC, said: "We're already seeing the impact of rapid genetic testing for patients who have had stroke or TIAs, with our colleagues in centres around the country telling us they need results quickly to inform their practice and avoid delays to discharge. The evidence bases for genotype guided antiplatelet therapy in cardiovascular disease is arguably even stronger than for patients who have stroke or TIA. The Guide PCI programme is a logical extension of our pharmacogenomics programme an

So much coming

+CE MARK

+FDA APPROVAL

+UK Expansion

+Europe Expansion

+US Expansion

+UAE Expansion as per LinkedIn

+National rollout in UK for Stroke testing

+National rollout in the UK for cardiovascular testing

+New contracts

+Grants

+Other wildcards

Over £3.0M in the coffers + additional revenues and grant cash = fully funded for 2025.

Now revenues growing on top.

Great stuff overall.

Last year 3 bags after the raise. I fancy 15-20 bags this time considering the magnitude of expansion coming here from both domestic and overseas.

Endorsement is huge.

Dr Gino Miele, CEO of genedrive plc, said: "We are delighted that our CYP2C19 rapid genetic test is being assessed for use in ACS and PCI procedures in addition to current clinical recommendations by NICE for use prior to prescription of Clopidogrel in IS and TIA. With clinical recommendations for CYP2C19 genetic testing for IS, TIA and ACS, and with rapid genetic testing within 24 hours being recommended if clopidogrel is being considered, our CYP2C19 test is well positioned to enable this intervention and care pathway change, significantly improving patient outcomes whilst at the same time freeing healthcare resources and finances."

Dr Jaydeep Sarma, Consultant Interventional Cardiologist in Greater Manchester, said: "The Greater Manchester Regional Primary PCI service operates 24 hours a day, 7 days a week, 365 days a year. Thousands of patients are seen rapidly for life saving interventions from across the region each year and it's essential that their treatments are optimised as quicky as possible. Integration of this rapid test into routine practice means we can get patients on the right treatment the first time, improving outcomes for our patients and the service as a whole."

Professor Maciej Tomaszewski, Deputy Director at the British Heart Foundation Manchester Centre of Research Excellence, said: "This is fantastic example of pharmacogenomics research in action, which has the potential to change clinical practice in cardiology clinics, wards and hospitals. The BHF Manchester CRE supports cardiovascular pharmacogenomics research and the follow up implementation programmes across the spectrum of cardiovascular diseases."

Bill Newman, Professor of Translational Genomic Medicine at University of Manchester, Consultant in Genomic Medicine at MFT, and a researcher with the National Institute for Health and Care Research (NIHR) Manchester BRC, said: "We're already seeing the impact of rapid genetic testing for patients who have had stroke or TIAs, with our colleagues in centres around the country telling us they need results quickly to inform their practice and avoid delays to discharge. The evidence bases for genotype guided antiplatelet therapy in cardiovascular disease is arguably even stronger than for patients who have stroke or TIA. The Guide PCI programme is a logical extension of our pharmacogenomics programme an

All whilst everyone knows its GLENCORE valued over 35BIL

GLENCORE came in without warning and didn't come in to be pretty or have their name tied to something they had no intention of seeing through.

They have a strong track record of seeing LOI's through to partnership.

I anticipate a big update on intergration and Monday next week would feel right.

Given this company is now in bed with Samsung it appears and has just shown the strength in its technology I see a MASSIVE undervaluation going on.

Especially as its debt free and is in full turnaround mode.

Looking for 1.00p by the time the year is out. The capitalisation at 1.00p is still tiny for a world leader in supercapacitors.

Once it breaches 1.00p on any kind of positive momentum t will keep going of course and head to 2.00-3.00p

I have great confidence here

Remember SUPERCAPACITORS will play a key role in AI infastructure for Nvidia.

https://www.trendforce.com/news/2025/03/25/news-nvidia-gb300-ignites-supercapacitor-push-among-leading-taiwanese-suppliers/

Dr Cooley's other company GELION is delivering both exceptional technology news and revenue growth.

Some facts:

GELION has 3x the market cap of CAP-XX

CAP-XX has higher revenues than GELION

CAP-XX is also exploring next generation technology for energy like GELION

Cooley is Chairman for CAP-XX and thus believes strongly in the trajectory

Cooley has 10 times the amount invested in CAP-XX compared to GELION

Remains one of the best opportunities in small caps considering the foundation for a explosive turnaround and technology news

Updated Schurter holding essentially 5% of the comapny. Who knows, maybe they are building to 10-20% of CAPx.

Keep an eye out for those delayed trades and after market buys....

+Resolved litigation

+Decreased costs massively

+Increased revenues

+Had Schurter AG buy 5% of the company

+New Chairman owns 10% of all stock

+Completed phase 1 of Schurter agreement

+Begun phase 2 of the Schurter agreement

+Begun development of next generation supercapacitors which can rerate the company shares to substantially higher levels

+Agreement with Farnell

+Agreement with Waldom

+Agreements with several others

+Signalled positive SMT progress

+Made good managment changes

+Signalled 24 months cash from Feb 2025

+Major tarrif advantagee oveer competition due to being made in Austrlia

+Supercapacitor market seeing YoY grwoth, CPX now very well positioned to grow market share

+Now major tech contract probably Sony or Samsung

+More.

Will rerate hard from here in 2025 imv. DYOR not advice

On the road to £50m cap this year chaps

Not just Cooley but also Schurter who are increasing their holding at every opportunity.

We know its Samsung or Sony.

Finish the week above 0.20+ and above 0.30+ this month and 1.00+ in 2025.

Absolutely Jimi

Most undervalued pharma now due a sharp correct north

Very undervalued here given the plethora of avenues this company is in.

In absolutely huge markets and institutions already.